NovoCure outlines $675M-$705M 2026 revenue target as new indications fuel growth
Source: SeekingAlpha
2026-02-26 11:18:39 ET
More on NovoCure
- NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
- NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
- Why NovoCure Is No Longer A Clear Sell At These Lows
- NovoCure Q4 2025 Earnings Preview
- Novocure shares surge after FDA approves Optune Pax for pancreatic cancer
Read the full article on Seeking Alpha
For further details see:
NovoCure outlines $675M–$705M 2026 revenue target as new indications fuel growth
NovoCure Limited
NASDAQ: NVCR
NVCR Trading
-2.85% G/L:
$12.775 Last:
483,163 Volume:
$12.60 Open:
NVCR Latest News
March 02, 2026 07:00:00 am
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
February 26, 2026 07:00:00 am
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
NVCR Stock Data
$1,170,211,701
105,800,576
0.07%
77
N/A
Medical Equipment & Supplies
Healthcare
JE
St. Helier
